Clinical Trial for Advanced Malignancies and Advanced Cancer.

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Advanced Malignancies, Advanced Cancer

Sex

Male or Female

Age

18+ years

Healthy participants

Visit ClinicalTrials.gov for more information

Eligibility criteria

Inclusion criteria

Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)

Measurable disease based on IMWG criteria as defined by at least 1 of the following:

Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Exclusion criteria

Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
Active or suspected cerebral/meningeal disease related to the underlying malignancy.
Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).

Study overview

This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.

The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.

Join PfizerConnect

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Join PfizerConnect

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Are you a Healthcare Professional?